Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:07 PM
Ignite Modification Date:
2025-12-24 @ 10:07 PM
NCT ID:
NCT02900235
Eligibility Criteria:
Inclusion Criteria:
* Able to provide written informed consent to participate in the study
* Caucasian male aged at least 35 years at Screening
* Healthy and free from clinically significant illness or disease at Screening and Day-1
* A body weight of 60 to 110 kg at Screening and Day-1
* Vital signs within the following ranges at Screening, Day-1 and Pre-dose:
* Body temperature : 35.0°C to 37.5°C
* Systolic blood pressure: 90 to 140 mmHg
* Diastolic blood pressure: 50 to 90 mmHg
* Regular daily bowel movements
Exclusion Criteria:
* Presence or history of severe adverse reaction or allergy to any medicinal product
* Participation in more than three clinical studies of an Investigational Medicinal Product (IMP) in the previous year or participated in a clinical study of any IMP within 12 weeks or five half-lives
* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardise the subject in case of participation in the study. The Investigator should be guided by evidence of any of the following:
* History of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding considered clinically significant by the Investigator
* History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bowel resection
* History or clinical evidence of pancreatic injury or pancreatitis
Healthy Volunteers:
True
Sex:
MALE
Minimum Age:
35 Years
Study:
NCT02900235
Study Brief:
Protocol Section:
NCT02900235